Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Heron Therapeutics Inc. News

    2,64 $ -2,76% -0,075 $
    In : 2,4774 € | 19.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1XB6K
    ISIN: US4277461020
    US-Symbol: HRTX
    Typ: Aktie

    Heron Therapeutics Inc. News

    11.04.24 - PR Newswire
    Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
    Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire
    28.03.24 - PR Newswire
    Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
    Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire
    12.03.24 - PR Newswire
    Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
    Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates PR Newswire
    28.02.24 - PR Newswire
    Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
    Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 PR Newswire
    23.01.24 - PR Newswire
    Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
    Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures PR Newswire
    07.01.24 - PR Newswire
    Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
    Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-​Opioid Dual Acting Local Anesthetic ...
    14.11.23 - PR Newswire
    Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
    Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance PR Newswire
    07.11.23 - PR Newswire
    Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
    Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 PR Newswire
    14.08.23 - PR Newswire
    Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
    Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates PR Newswire
    24.07.23 - PR Newswire
    Heron Therapeutics Announces Cost Reduction Plan and Restructuring
    Heron Therapeutics Announces Cost Reduction Plan and Restructuring PR Newswire
    24.07.23 - PR Newswire
    Heron Therapeutics Announces $30 Million Private Placement Financing
    Heron Therapeutics Announces $30 Million Private Placement Financing PR Newswire
    23.06.23 - PR Newswire
    Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
    Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer PR Newswire
    12.06.23 - PR Newswire
    Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer
    Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer PR Newswire
    11.05.23 - PR Newswire
    Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates
    Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates PR Newswire
    04.05.23 - PR Newswire
    Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
    Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 PR Newswire
    20.04.23 - PR Newswire
    Heron Therapeutics Announces Commercial Leadership Changes
    Heron Therapeutics Announces Commercial Leadership Changes PR Newswire
    17.04.23 - PR Newswire
    Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference
    Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference PR Newswire
    03.04.23 - PR Newswire
    Heron Therapeutics Announces New CEO and Board Chairman
    Heron Therapeutics Announces New CEO and Board Chairman PR Newswire
    23.03.23 - PR Newswire
    Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
    Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates PR Newswire
    13.03.23 - PR Newswire
    Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023
    Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-​through Payment Status for APONVIE™, Effective April 1, 2023 PR Newswire

    Newssuche

    Videos

    newspaper
    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »